Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
PHASE1CompletedINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
June 30, 2005
Conditions
Malignant Brain TumorBrain Stem Glioma,
Interventions
DRUG
Tarceva (Erlotinib Hydrochloride)
tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
Trial Locations (1)
94805
Institut Gustave Roussy, Villejuif
All Listed Sponsors
lead
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
NCT00418327 - Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma | Biotech Hunter | Biotech Hunter